Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

WHAT'S NEW

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Sep 24 2018

Full Issue

FDA Lacks Funding, Staffing To Properly Regulate Pharmaceutical Compounders, Top Agency Official Claims

The agency is tasked with making sure that compounded drugs, which are made at facilities that don’t have to meet the same standards as regular drug manufacturers, are safe. Director of the Center for Drug Evaluation and Research Janet Woodcock says that her inspectors are seeing concerning problems, but lacks resources to be truly effective.

Stat: 'Stuff Floating' In Compounded Drugs Prompts FDA To Appeal For More Funding 

The Food and Drug Administration doesn’t have enough funding or staff to properly regulate pharmaceutical compounders, a top agency official said Friday, describing inspections that turned up “stuff floating around” in supposedly sterile shipments. The program doesn’t “have adequate core staffing,” said Janet Woodcock, director of the Center for Drug Evaluation and Research, on Friday, adding that it’s one of the center’s programs that is “suffering the most.” (Swetlitz and Florko, 9/21)

In other pharmaceutical news —

Stat: FDA Orders Pharma Lab To Shut Down In-House Microbrewery 

There’s trouble brewing in the Chicago suburbs, where the FDA has served up another round of warnings to a pharmaceutical laboratory using its space to craft small-batch beer. A recent inspection of Pharmaceutical Laboratories and Consultants Inc., in Addison, Ill., found brewery supplies casually mixed in with equipment used to evaluate over-the-counter drug products. In one instance, the facility had stored a beer fermenter and created a workspace for a brewery employee preparing kegs, all within 10 feet of an area where microbiological material is kept. (Facher, 9/21)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, June 29
  • Friday, June 26
  • Thursday, June 25
  • Wednesday, June 24
  • Tuesday, June 23
  • Monday, June 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF